Supplement Interactions with Blood Pressure Medications
High blood pressure (hypertension) affects nearly half of U.S. adults. Several supplements commonly used by people with hypertension — potassium, magnesium, CoQ10, hawthorn, licorice root, and St. John's wort — can interact with blood pressure medications. Some interactions are mild. A few are dangerous. Most patients do not tell their doctor what supplements they take, and most clinicians do not ask. The result is preventable harm.
Potassium: The Double-Edged Mineral
ACE inhibitors (lisinopril, enalapril, ramipril) and ARBs (losartan, valsartan, telmisartan) raise blood potassium because they reduce aldosterone, the hormone that drives potassium excretion. Adding potassium supplements — or potassium-based salt substitutes such as “NoSalt” — on top of these drugs can cause hyperkalemia, an elevated blood potassium that can trigger fatal cardiac arrhythmias. The risk multiplies when potassium-sparing diuretics (spironolactone, eplerenone, amiloride) are also in use. Patients on these drug classes should not take potassium supplements without lab monitoring and physician oversight (Raebel 2012 PMID 22555185).
Licorice Root: The Underappreciated Risk
Licorice root contains glycyrrhizin, which inhibits the enzyme 11β-hydroxysteroid dehydrogenase type 2. This produces a mineralocorticoid excess–like state — the body acts as if it has too much aldosterone, which raises blood pressure, lowers potassium, and can cause weakness, edema, and cardiac arrhythmia (Sigurjónsdóttir 2003 PMID 12624617; EFSA 2014 Compendium of Botanicals). The European Food Safety Authority and the Scientific Committee on Food set 100 mg/day glycyrrhizin as a level above which adverse effects become more likely, and clinical pseudoaldosteronism has been reported at sustained intakes of about 100–200 mg/day. Licorice and its extracts are common in “adrenal support,” “cortisol balance,” and herbal stomach formulas where it is not always prominent on the label. Deglycyrrhizinated licorice (DGL) is the safer form for people on antihypertensives.
Magnesium, Hawthorn, CoQ10, and St. John's Wort
Magnesium supplementation has a small blood-pressure-lowering effect and is generally safe with antihypertensives; the main caution is hypermagnesemia in patients with reduced kidney function or those on potassium-sparing diuretics. Hawthorn (Crataegus) extracts have additive effects with antihypertensives and with digoxin and may produce excessive blood-pressure reduction (Tassell 2010 PMID 22228951). CoQ10 (ubiquinone) produces a modest blood-pressure reduction in some trials — the 2007 Rosenfeldt meta-analysis (PMID 17287847) reported pooled systolic BP reductions of about 16 mmHg, but a more conservative 2016 Cochrane review (Ho 2016 PMID 26935713) found the evidence insufficient to support a clear effect. CoQ10's structural similarity to vitamin K means it can reduce the anticoagulant effect of warfarin and may require INR monitoring (Engelsen 2003 PMID 12625571). St. John's wort induces CYP3A4 and P-glycoprotein and can lower blood levels of calcium-channel blockers (e.g., nifedipine, verapamil) and several other antihypertensives, reducing their effect (Russo 2014 PMID 24033819).
What To Do
Bring every supplement bottle to your next blood-pressure visit, including herbal teas. Ask your pharmacist to run an interaction check — pharmacists are usually faster and more accurate than apps. If you take an ACE inhibitor, ARB, or potassium-sparing diuretic, do not add potassium supplements or potassium-based salt substitutes without your clinician's say-so.
Sources
- Raebel MA. “Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.” Cardiovascular Therapeutics, 2012;30(3):e156-66. PMID 22555185.
- Sigurjónsdóttir HÁ, et al. “Liquorice-induced rise in blood pressure: a linear dose-response relationship.” Journal of Human Hypertension, 2003;17(2):125-131. PMID 12624617.
- European Food Safety Authority (EFSA). “Compendium of botanicals reported to contain naturally occurring substances of possible concern for human health when used in food and food supplements.” EFSA Journal, 2012 (updated 2024).
- Houston M. “The role of magnesium in hypertension and cardiovascular disease.” Journal of Clinical Hypertension, 2011;13(11):843-847. PMID 22051430.
- Tassell MC, et al. “Hawthorn (Crataegus spp.) in the treatment of cardiovascular disease.” Pharmacognosy Reviews, 2010;4(7):32-41. PMID 22228951.
- Ho MJ, et al. “Coenzyme Q10 supplementation for hypertension.” Cochrane Database of Systematic Reviews, 2016;(3):CD007435. PMID 26935713.
- Engelsen J, et al. “Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin-treated outpatients.” Thrombosis and Haemostasis, 2003;87(6):1075-1076. PMID 12625571.
- Russo E, et al. “Hypericum perforatum: pharmacokinetic, mechanism of action, tolerability, and clinical drug-drug interactions.” Phytotherapy Research, 2014;28(5):643-655. PMID 24033819.
- U.S. Food and Drug Administration. “Black licorice: trick or treat?” FDA Consumer Update, October 2017 (reaffirmed 2023).
Reviewed against 9 peer-reviewed and regulatory sources (safety-category rigor).